---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-002636"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T21:59:36.097658+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio secures $500M royalty financing for acoramidis and $450M term loan, repays existing debt

## Summary
- Funding Agreement: $500M from LSI/CPPIB upon FDA approval of acoramidis; 5% royalty on global net sales, cap $950M.
- Financing Agreement: $450M initial term loan funded (up to $300M incremental) from Blue Owl; SOFR+6.75% or base+5.75% interest; matures Jan 17, 2029.
- Existing $450M loan from Nov 2021 repaid and terminated using initial term loan proceeds and cash on hand.
- Minimum cash covenant of $70M; prepayment fees up to 3% plus make-whole; two springing maturities tied to convertible notes.
- Funding terminates if FDA approval of acoramidis does not occur by May 15, 2025, with no penalty.

## SEC filing metadata
- accession: 0001140361-24-002636
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/0001140361-24-002636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/ef20019054_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-002636
- JSON: https://secwatch.observer/filing/0001140361-24-002636.json
- Plain text: https://secwatch.observer/filing/0001140361-24-002636.txt

## Key facts
- Debt Financings
  BridgeBio Pharma, Inc. incurred term loan of $450,000,000 with Blue Owl Capital Corporation, as administrative agent at Term SOFR plus 6.75% maturing January 17, 2029.
  - Instrument: term loan
  - Principal: $450,000,000
  - Counterparty: Blue Owl Capital Corporation, as administrative agent
  - Rate: Term SOFR plus 6.75%
  - Maturity: January 17, 2029
  - Event: incurrence
  source text: On the Closing Date, the Company entered into a Financing Agreement (the “Financing Agreement”) with certain of its subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders (the “Administrative Agent”). Pursuant to the terms and conditions of the Financing Agreement, the Lenders have agreed to extend a senior secured credit facility to the Company in an aggregate principal amount of up to $750,000,000, comprised of (i) an initial term loan in an aggregate principal amount of $450,000,000 (the “Initial Term Loan”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/0001140361-24-002636-index.htm
- Material Agreements
  BridgeBio Pharma, Inc. entered into Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. valued at $500,000,000 (effective 2024-01-17).
  - Action: entry
  - Counterparty: LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l.
  - Value: $500,000,000
  - Effective: 2024-01-17
  source text: entered into a Funding Agreement (the “Funding Agreement”) with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. (together, the “Purchasers”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/0001140361-24-002636-index.htm
- Material Agreements
  BridgeBio Pharma, Inc. entered into Financing Agreement with Blue Owl Capital Corporation, as administrative agent valued at $750,000,000 (effective 2024-01-17).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Blue Owl Capital Corporation, as administrative agent
  - Value: $750,000,000
  - Effective: 2024-01-17
  source text: On the Closing Date, the Company entered into a Financing Agreement (the “Financing Agreement”) with certain of its subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/0001140361-24-002636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.